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outcomes. Regarding the acceptability threshold in Poland cysteamine therapy 
can be considered a cost-effective technology compared with CaST in patients 
who began treatment before the age of two.
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anaESthEtiSEd PatiEntS undErgoing ElECtivE SurgErY in England 
and walES
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Objectives: To assess the cost-effectiveness of sugammadex compared with 
neostigmine + glycopyrrolate as a reversal agent for moderate and deep rocu-
ronium or vecuronium-induced neuromuscular blockade (NMB) in the elective 
setting in England and Wales, when extubation occurs at a train-of-four (TOF) ratio 
of 0.9. MethOds: A decision tree comparing the cost-effectiveness of sugamma-
dex versus neostigmine + glycopyrrolate when reversing moderate or deep NMB 
induced by commonly used neuromuscular blocking agents (NMBAs) (atracurium/
rocuronium/vecuronium) was developed. Extubation was modelled to occur at a 
TOF ratio of 0.9, as may happen when using objective NMB monitoring to deter-
mine when to safely extubate. Time to recovery was used to calculate the cost 
of patients recovering in theatre based on both the average cost per minute of 
theatre time, and operating room (OR) staff costs per minute. Effectiveness was 
measured by the number of prolonged paralysis cases prevented by each treat-
ment regimen. Results: Reversal of moderate NMB: when considering average 
cost per minute of theatre time, results show that sugammadex strategies are 
dominant compared with all assessed comparators. When considering OR staff 
cost per minute, results show that rocuronium with sugammadex is dominant 
over all assessed comparators, with the exception of atracurium with neostigmine 
+ glycopyrrolate (ICER< £100). Reversal of deep NMB: when considering either 
costing scenario, results show that sugammadex strategies are dominant over 
all assessed comparators, with the exception of atracurium with neostigmine + 
glycopyrrolate (ICER < £330). cOnclusiOns: In clinical settings where extubation 
occurs at a TOF ratio of 0.9, and time savings may be realized for all OR staff, under 
both moderate and deep NMB scenarios in the elective surgery setting, sugam-
madex is either dominant or shows reasonable levels of cost-effectiveness (with 
low ICERs < £330 when not dominant against neostigmine+ glycopyrrolate), whilst 
also filling an unmet need for deep NMB reversal.
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CoSt-EffECtivEnESS analYSiS of a vaCCination ProgrammE for thE 
PrEvEntion of hErPES ZoStEr and PoSt-hErPEtiC nEuralgia in adultS 
agEd 50 and ovEr in gErmanY
Largeron N.1, Préaud E.1, Boehm K.2, Aidelsburger P.2, Anger D.3, Bianic F.3
1Sanofi Pasteur MSD, Lyon, France, 2CAREM GmbH, Sauerlach, Germany, 3OptumInsight, 
Nanterre, France
Objectives: A vaccine is licensed in Europe for the prevention of Herpes Zoster 
(HZ) and postherpetic neuralgia (PHN) in adults aged ≥ 50 years. The objective of 
this study was to assess the cost-effectiveness of a vaccination programme in 
Germany in this population. MethOds: An existing European Markov Model was 
adapted to the German health care setting and cost-effectiveness outcomes were 
assessed from the statutory health insurance (SHI) and from the societal perspec-
tive. The Markov Model compares a HZ vaccination policy for adults aged ≥ 50 
years with a no vaccination policy. Health states considered are healthy, HZ, PHN, 
healthy post-HZ and death. HZ and PHN states are further split by pain severity 
(mild, moderate or severe). Model outcomes include cost/HZ case avoided, cost/
PHN case avoided and cost/quality-adjusted life year (QALY) gained. Additionally 
we assessed the number needed to vaccinate (NNV) to avoid one case of HZ or PHN. 
Input data were obtained from German data sources, international and German 
study results as well as published literature. Discounting was done in accordance 
to guidelines from the German Institute for Quality and Efficiency in Health Care 
(IQWiG). Results: Preliminary results of the base-case analysis show incremen-
tal cost-effectiveness and cost-utility ratios (ICER) in amount of € 2,223 per HZ 
case avoided and € 22,923 per QALY gained from a payer perspective. In sensitiv-
ity analyses discount rates, vaccine prices and no hospitalization assumption 
showed a major impact on the results. cOnclusiOns: Our cost-effectiveness 
analysis shows that a HZ vaccination policy for adults aged ≥ 50 years in Germany 
could provide public health and economic effects in the German health care 
system.
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Objectives: An increased risk for fractures has been observed in patients 
treated with opiates, possibly resulting from falls related to central nervous 
system effects, such as dizziness. Observational data suggest that the semisyn-
thetic opioid, buprenorphine, may be associated with a lower fracture risk than 
some other opiates such as tramadol. Our objective was to perform a preliminary 
analysis to explore whether a buprenorphine-class drug has the potential to be 
cost-effective due to a reduced risk for fracture. MethOds: Decision-analytic 
modeling was used to project fracture-related outcomes and costs over 1 year. 
Quality-adjusted life-years (QALYs) and costs (in 2012 pounds sterling) were esti-
mated from a health service perspective. Odds ratios for forearm, hip, and spine 
fractures, by drug, estimated from real-world hospital discharge data (Vestergaard 
et al., 2006), were applied to the risk for fracture in the general population. 
ing ponatinib provided more than double (2.2-fold) the MCyR months at 36% 
higher cost compared to the 2G TKI strategy. The average cost/MCyR month 
with ponatinib was lower than the average cost/MCyR month with 2G TKIs. 
While there are limitations with the methology and assumptions of the model, 
this analysis suggests treatment with ponatinib may provide good value for 
ponatinib-eligible Italian patients.
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Objectives: To estimate the cost-effectiveness of using the capsaicin patch 
QUTENZATM prior to use of more costly neuropathic pain medications for individu-
als with peripheral neuropathic pain (PnP). MethOds: A decision tree and Markov 
model was developed using inputs from a prospective, observational study. This 
study provided estimates of clinical efficacy, health utility and resource use. The 
model considered two treatment strategies: 1. a capsaicin patch followed by pre-
gabalin and then a subsequent last-line therapy, and 2. no exposure to a capsaicin 
patch. A systematic review and meta-analysis were used to estimate the effective-
ness of pregabalin. Response was defined as a ≥ 50% reduction in pain at week-8. 
Patients who responded were assumed to experience pain relief and increase in 
health-related quality of life until the resolution of pain (or death). Non-responders 
were assumed to switch therapy, and individual’s that failed last-line therapy were 
assumed to experience baseline pain (unless resolution of pain or death). Costs 
were based on published sources. The primary outcome was the incremental cost-
effectiveness ratio (ICER). The perspective was the UK National Health Service and 
personal social services. Results: Key parameter estimates derived from the 
observational study were: the probability of response for capsaicin patch (29.5%), 
the mean number of patches per application (1.5), the mean time to retreatment 
(218 days), The baseline EQ-5D score was 0.370; response was associated with an 
increase in EQ-5D utility of 0.353 from baseline. The base-case ICER was £2,292 per 
quality-adjusted life-year (QALY). This varied by time horizon. Probabilistic sensi-
tivity analysis suggested that over a lifetime horizon, a treatment strategy placing 
capsaicin patches before pregabalin had a 99.9% probability of being cost effective 
at a willingness-to-pay threshold of £20,000. cOnclusiOns: The capsaicin patch 
used before pregabalin was a highly cost-effective treatment in the management 
of peripheral neuropathic pain.
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Objectives: To evaluate the cost effectivenss of Thiopentone and Propofol for over 
night induction anesthesia in a tertiary care hospital. MethOds: A prospective 
observational study in which the patients scheduled for general anaesthesia were 
adminsitred EQ5D 5L(Qol question aire) after six hour and 24 hours of administering 
Induction Aneasthesia. Kuppuswamy scale was applied to asses the socioeconomic 
status along with the demographic detials Results: The average of EQ5D5L scores 
for Propofal was 14.2 and for Thiopentone 16.0. The cost of the Propofol brand used 
in hospital were 250INR and 260INR. Thiopentone , only one brand was avialable 
costing 62 INR. The Propofol was the most commonly used induction anesthetic 
and it costs more than 4 times of Thipentone. The patients socioeconomic catego-
rirzation based on Kuppuswmy Scale revealed nearly 50% of patients belonged to 
lower middle class and 35% middle class and rest of the patients to Upper class. 
Incremental cost effectivness ratio for Thiopentone agianst Propofol was found 
to be -110; cOnclusiOns: The Propofol although expensive does not offer any 
advantage over the Thiopentone as for quality of life among patients who under 
went induction anethesia
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Objectives: To perform a cost-effectiveness analysis (CEA) of cysteamine in the 
treatment of infantile cystinosis vs. control group consisting of patients who had 
been given only conservative and symptomatic treatment (CaST). MethOds: 
Markov model was developed in TreeAge Pro 2009. The model evaluated the costs 
and health outcomes of cysteamine treatment at a dose of 1.30 g/m2/day com-
pared with the use of CaST. The model distinguished two populations, depending 
on the time of initiation of the treatment (before the age of two – P1 and after 
the age of two – P2, which implies worse prognosis for the time of occurrence of 
end stage renal disease (ESRD)). The CEA was conducted from both a common 
payer perspective (a patient and a public payer) and a public payer perspective. 
The time horizon of the analysis covered the period from the age of one or four 
(depending on the start of cysteamine therapy) to fifty (currently, the oldest liv-
ing patients with cystinosis reach the fifth decade of life). The main measures 
of the outcomes in the CEA were life-years gained (LYG) and life-years gained to 
the onset of ESRD. Results: From the common payer perspective the cost per 
LYG was PLN 95,337 and PLN 192,272, respectively for the population P1 and P2. 
Cost of LYG to the onset of ESRD was PLN 33,317 and PLN 64,163, respectively for 
populations P1 and P2. The results obtained from the public payer perspective 
did not differ significantly from the results obtained from the common payer 
perspective. cOnclusiOns: Cysteamine treatment of patients with cystinosis vs. 
therapy involving only CaST is more expensive, however produces better health 
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cost of blood production accounted only for the resources expended for collection, 
processing, laboratory testing, storage, as well as the indirect donor’s productivity 
loss. Hence, the cost associated to donor recruitment, pre-transfusion preparation, 
transfusion administration, follow up management of adverse events, and other 
long-term relevant costs were not taken into consideration. Two separate question-
naires were used to collect data regarding: personnel time, annual blood quantities 
collected, percentage of wastage, consumables utilization, institutional overheads, 
information technology expenditure, medical equipment utilized, nuclear acid tests, 
other laboratory tests and indirect costs. Data gather by 53 hospitals across the 
country. An economic model was build using also economic data collected by the 
National School of Public Health and the Ministry of Health. All data referred to the 
year 2012. Results: The cost distribution was positively skewed (skewness:1.530). 
The unweighted mean cost of collecting a blood unit was estimated at € 146.43 
(standard deviation: +€ 28.18, min/max: € 110.25-€ 240.84). In addition, the indirect cost 
of donors’ loss of productivity was estimated at € 33,70 (+€ 49,23). Major cost compo-
nent appears to be the cost of personnel, which was estimated at € 46.86 (+€ 24.86, 
€ 16.49-€ 132.59), accounting for 32.0% of the total direct cost. The average of blood 
unit wastage was estimated at 4.90%. There were not differences between the cost 
of producing a unit of blood in Athens compared with the rest of the country (Man-
Whitney test, p-value: 0.341). cOnclusiOns: This study indicates that the cost of 
producing a cost of blood isn’t insignificant. These figures need to be complemented 
with those concerning the cost of transfusion to have a full picture of producing 
and using a cost of blood locally.
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Objectives: The significance of cystic fibrosis associated with early disability, 
the need for long-term regular treatment and follow-up and is associated with 
high costs. Data reflecting the socio-economic burden of cystic fibrosis in Russia is 
low, which dictates the need for clinical and economic studies, for example – this 
study. MethOds: An assessment of the burden of cystic fibrosis with the use of 
tobramycin inhalation solution from different manufacturers and powder inhaled 
tobramycin (Tobi Podhaler) for the treatment of Pseudomonas infections in patients 
with cystic fibrosis. The study took into account only the direct medical costs of one 
patient based on standards of outpatient and inpatient care for patients with cystic 
fibrosis. Results: The burden of cystic fibrosis with the use of tobramycin powder 
for inhalation Tobi Podhaler with the time horizon of 10 years is reduced faster 
than in similar groups of patients: the point of profitability is on the eighth year of 
treatment when compared with tobramycin-Gobbi and a 9-year - with Bramitobom, 
when the use of Tobi Podhaler requires less cost to 46,372 USD and 50,138, respec-
tively. cOnclusiOns: Additional costs are difficult to calculate due to the fact that 
tobramycin solution for inhalation requires compliance with ‘‘cold chain’’ at all 
stages of the life cycle of the product: transportation, storage at the distributor and 
at the pharmacy, storage at home. Thus, obtained data in controlled efficacy studies 
of tobramycin solution in actual practice, may be significantly lower.
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Objectives: To evaluate the cost-effectiveness of prolonged release oxycodone/
naloxone combination tablets [OXN; naloxone is added to counteract opioid-induced 
constipation (OIC)] in patients who are constipated despite the use of two laxatives, 
compared with prolonged release oxycodone (OXY) alone. MethOds: A model used 
data from one phase II randomised, controlled trial (RCT) in patients with moder-
ate/severe cancer pain and a pooled analysis of two phase III RCT’s in patients with 
moderate/severe non-cancer pain. A subgroup of patients with OIC who had failed on 
two or more laxatives at screening was applied in the analysis (n= 178). The drug cost 
for pain therapy was combined with laxative costs and other resources to calculate 
the cost difference between OXN and OXY. Quality-adjusted life-year (QALY) gains 
were calculated by mapping Bowel Function Index scores to EQ-5D utility values. 
Deterministic sensitivity analyses were performed. The analysis was conducted from 
the perspective of the UK National Health Service (NHS). Results: The incremental 
cost of OXN vs. OXY was £409.60 for the average treatment duration of 301 days. OXN 
gave an incremental QALY gain of 0.0524. The estimated incremental cost-effective-
ness ratio (ICER) was £7,821.80 for OXN vs. OXY. The ICER remained below £30,000 for 
all sensitivity analyses, with OXN dominating OXY in some scenarios when higher 
constipation unit costs were applied. cOnclusiOns: Patients treated with OXN 
experienced a quality of life gain, and OXN had an ICER considerably below thresholds 
normally regarded as cost-effective in the UK (£20,000 – 30,000/QALY). More research 
is required into the cost of treating OIC, with OXN dominating OXY (total cost saving 
to the NHS and quality of life benefit) in sensitivity on OIC unit costs. OXN is therefore 
estimated to be a cost-effective option for treating patients with moderate to severe 
pain and OIC, who are constipated despite the use of two laxatives.
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Drug costs were based on the 10-μ g per hour buprenorphine patch and the equiv-
alent tramadol dose (2013 British National Formulary listings). Fracture costs 
were from a recent National Institute of Health and Care Excellence submission; 
utility weights were obtained from the literature. Results: For a population of 
100,000, the model predicted a reduction in the number of additional fractures 
(forearm, hip, or spine) associated with analgesic use from over 2,000 for patients 
treated with tramadol to under 20 for patients treated with buprenorphine. An 
estimated £5.5 million was saved and over 1,300 QALYs were gained. In sensitiv-
ity analysis, buprenorphine was dominant in most analyses and most sensitive 
to treatment duration. The cost-effectiveness estimate was below £20,000 per 
QALY in all scenarios. cOnclusiOns: Our preliminary analysis suggests that 
buprenorphine has the potential to be dominant and cost-effective, compared 
with tramadol.
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Kanters T.A.1, Plug I.2, Rutten-van Mölken M.P.M.H.1, Redekop W.1, Van der Ploeg A.T.2, 
Hakkaart L.1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Erasmus University Medical 
Center, Rotterdam, The Netherlands
Objectives: Infantile Pompe disease is a rare metabolic disease. Enzyme replace-
ment therapy (ERT) has proven to have substantial effects on survival in infantile 
Pompe disease. However, costs of therapy are very high. This paper assesses the 
cost-effectiveness of ERT in infantile Pompe disease. MethOds: A patient simula-
tion model was used to compare costs and effects of ERT with costs and effects 
of supportive therapy (ST). The model was filled with data on survival, quality of 
life and costs. For both arms of the model, data on survival were obtained from 
international literature. In addition, survival as observed among 20 infantile Dutch 
patients, who all received ERT, was used. Quality of life was assumed to be the 
same in both groups and was measured using the EQ-5D. Costs included the costs 
of ERT, which depend on a child’s weight, and costs of health care use, informal 
care and infusions. A lifetime time horizon was used, with semi-annual time 
cycles. Results: On average, ST receiving patients were modelled not to survive 
the first half year of life; whereas the life expectancy in the ERT patients was 
modelled to be almost 14 years. Lifetime incremental QALYs were 6.7. Incremental 
costs were estimated to be € 7.0 million, consisting for 95% of treatment costs. 
The incremental costs per QALY were estimated to be € 1.0 million. The incremen-
tal cost per life year gained was estimated to be € 0.5 million. cOnclusiOns: In 
2012, the Dutch health care insurance board advised the Minister of Health to 
reimburse enzyme replacement therapy in Pompe disease, despite its unfavorable 
ICER. Other factors, such as the rarity of the disease, equity considerations, and 
the relatively modest budget impact have probably played a role in this decision. 
These and other factors could be incorporated in a formal multi-criteria decision 
analyses.
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Objectives: To estimate the incremental cost-effectiveness (ICER) and cost-util-
ity ratio (ICUR) of belimumab compared to standard care (SC) for the treatment 
of patients with Systemic Lupus Erythematosus (SLE) in Portugal. MethOds: A 
lifetime microsimulation model represented the complex and multidimensional 
course of SLE, based on long term data from a US cohort of SLE patients. The 
analysis was undertaken using a societal perspective with 5% discount rates 
for costs (direct and indirect costs), and effects [Life Years Gained (LYG) and 
QALY (Quality Adjusted Life Years)]. The model was calibrated with the phase 
III BLISS trials data, and UK utility values. The ICER and ICUR were estimated 
by comparison of SC vsSC with belimumab, with a lifetime analytic horizon. 
Belimumab non-responders were discontinued after 6 months and belimumab 
treatment was maximized at 3 years. Results: The model demonstrated that 
adding belimumab to SC to treat SLE patients with high disease activity, positive 
anti-dsDNA antibodies, and low complement (C3, C4) levels, would result in a 
potential gain of 0.41 life-years, and 0.32 QALYs. Incremental costs were€ 8,400, 
resulting in an ICER of € 20,649/LYG and ICUR of € 25,917/QALY for the base case 
scenario. ICER and ICUR are insensitive to the follow-up treatment costs of SLE, 
and wastage of drug; moderately sensitive to duration of treatment, and waning 
time; and very sensitive to discount rates, and exclusion of indirect costs. The 
probabilistic sensitivity analysis reveals a cost-effectiveness probability of 59% 
for a € 30,000/QALY threshold, and a median ICUR of € 27,932/QALY (95% confi-
dence interval: € 14,215/QALY - € 52,279/QALY). cOnclusiOns: The analysis sug-
gests that adding belimumab to SC for SLE patients with high disease activity, 
positive anti-dsDNA, and low complement levels, is cost-effective, presenting 
an ICER and ICUR below the commonly used threshold. This study is funded by 
GlaxoSmithKline, protocol #HO-13-13626
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Objectives: To estimate the cost of producing a unit of blood from a NHS and 
societal perspective in Greece. MethOds: In line with the official guidelines, the 
